Literature DB >> 31463100

Diagnostic value of CD206+CD14+ macrophages in diagnosis of lung cancer originated malignant pleural effusion.

Xue-Bin Pei1, Xiu-Zhi Wu1, Feng-Shuang Yi1, Kan Zhai1, Huan-Zhong Shi1.   

Abstract

BACKGROUND: Pleural effusions are common complications of various diseases. Patients with malignant pleural effusion (MPE) usually face poor prognosis and short life expectancy. Discriminating between MPE and benign pleural effusion remains to be difficult. The aim of our current study was to evaluate whether CD206+CD14+ macrophages could be a diagnostic biomarker for MPE.
METHODS: The percentages of CD14+, CD86+CD14+ and CD206+CD14+ macrophages in pleural effusions were determined by flow cytometry in 34 patients with MPE and 26 with benign pleural effusion, and their diagnostic performances were evaluated by receiver operating characteristic (ROC) curves.
RESULTS: The percentages of CD14+, CD86+CD14+ and CD206+CD14+ macrophages were remarkably higher in MPE than in benign pleural effusion (all P<0.05). With a cutoff value of 39.8%, a high sensitivity of 88.2% and high specificity of 100.0% were found in CD206+CD14+ macrophages to diagnose MPE. The area under the curve, positive predictive value and negative predictive value of CD206+CD14+ macrophages were 0.980 (95% CI, 0.905 to 0.999), 100.0 (88.4 to 100.0) and 86.7 (69.3 to 96.2), respectively. The diagnostic performance of CD206+CD14+ macrophages was more accurate than those of CD14+ and CD86+CD14+ macrophages.
CONCLUSIONS: CD206+CD14+ macrophages could be used to discriminate MPE from benign pleural effusion.

Entities:  

Keywords:  Biomarker; diagnosis; macrophages; malignant pleural effusion (MPE)

Year:  2019        PMID: 31463100      PMCID: PMC6688024          DOI: 10.21037/jtd.2019.06.44

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

1.  BTS guidelines for the investigation of a unilateral pleural effusion in adults.

Authors:  N A Maskell; R J A Butland
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

3.  Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010.

Authors:  Mark E Roberts; Edmund Neville; Richard G Berrisford; George Antunes; Nabeel J Ali
Journal:  Thorax       Date:  2010-08       Impact factor: 9.139

4.  Infiltration of CD14-positive macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis.

Authors:  Makoto Kinouchi; Koh Miura; Takayuki Mizoi; Kazuyuki Ishida; Wataru Fujibuchi; Toshinori Ando; Nobuki Yazaki; Kazuya Saito; Ken-ichi Shiiba; Iwao Sasaki
Journal:  Hepatogastroenterology       Date:  2011 Mar-Apr

Review 5.  Malignant pleural effusion, current and evolving approaches for its diagnosis and management.

Authors:  Siyamek Neragi-Miandoab
Journal:  Lung Cancer       Date:  2006-08-07       Impact factor: 5.705

6.  Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer.

Authors:  Ying Chen; Bin Liang; Yu-Jie Zhao; Shao-Cheng Wang; Yi-Bo Fan; Guang-Ping Wu
Journal:  Diagn Cytopathol       Date:  2010-10-26       Impact factor: 1.582

7.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Authors:  David G DeNardo; Donal J Brennan; Elton Rexhepaj; Brian Ruffell; Stephen L Shiao; Stephen F Madden; William M Gallagher; Nikhil Wadhwani; Scott D Keil; Sharfaa A Junaid; Hope S Rugo; E Shelley Hwang; Karin Jirström; Brian L West; Lisa M Coussens
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

8.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Authors:  Jonathan B Mitchem; Donal J Brennan; Brett L Knolhoff; Brian A Belt; Yu Zhu; Dominic E Sanford; Larisa Belaygorod; Danielle Carpenter; Lynne Collins; David Piwnica-Worms; Stephen Hewitt; Girish Mallya Udupi; William M Gallagher; Craig Wegner; Brian L West; Andrea Wang-Gillam; Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

Review 9.  Macrophage biology in development, homeostasis and disease.

Authors:  Thomas A Wynn; Ajay Chawla; Jeffrey W Pollard
Journal:  Nature       Date:  2013-04-25       Impact factor: 49.962

Review 10.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

View more
  4 in total

1.  Tumor cells express pauci- and oligomannosidic N-glycans in glycoproteins recognized by the mannose receptor (CD206).

Authors:  Kathrin Stavenhagen; Lisa C Laan; Chao Gao; Akul Y Mehta; Jamie Heimburg-Molinaro; Jonathan N Glickman; Irma van Die; Richard D Cummings
Journal:  Cell Mol Life Sci       Date:  2021-06-05       Impact factor: 9.261

2.  Single-cell analysis of diverse immune phenotypes in malignant pleural effusion.

Authors:  Zhong-Yin Huang; Ming-Ming Shao; Jian-Chu Zhang; Feng-Shuang Yi; Juan Du; Qiong Zhou; Feng-Yao Wu; Sha Li; Wei Li; Xian-Zhen Huang; Kan Zhai; Huan-Zhong Shi
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

3.  Recruitment of IL-1β-producing intermediate monocytes enhanced by C5a contributes to the development of malignant pleural effusion.

Authors:  Lisha Luo; Shuanglinzi Deng; Wei Tang; Xinyue Hu; Feifei Yin; Huan Ge; Jiale Tang; Zhonghua Liao; Xiaozhao Li; Juntao Feng
Journal:  Thorac Cancer       Date:  2022-02-08       Impact factor: 3.500

4.  Efferocytosis fuels malignant pleural effusion through TIMP1.

Authors:  Lilan Zhao; Anastasios D Giannou; Yang Xu; Ahmad Mustafa Shiri; Imke Liebold; Babett Steglich; Tanja Bedke; Tao Zhang; Jöran Lücke; Pasquale Scognamiglio; Jan Kempski; Anna Woestemeier; Jing Chen; Theodora Agalioti; Dimitra E Zazara; Diana Lindner; Melanie Janning; Jan K Hennigs; Rajesh M Jagirdar; Ourania S Kotsiou; Sotirios G Zarogiannis; Yasushi Kobayashi; Jacob R Izbicki; Sourav Ghosh; Carla V Rothlin; Lidia Bosurgi; Samuel Huber; Nicola Gagliani
Journal:  Sci Adv       Date:  2021-08-13       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.